MX2019005911A - Anticuerpos anti_cd137 novedosos y usos de estos. - Google Patents
Anticuerpos anti_cd137 novedosos y usos de estos.Info
- Publication number
- MX2019005911A MX2019005911A MX2019005911A MX2019005911A MX2019005911A MX 2019005911 A MX2019005911 A MX 2019005911A MX 2019005911 A MX2019005911 A MX 2019005911A MX 2019005911 A MX2019005911 A MX 2019005911A MX 2019005911 A MX2019005911 A MX 2019005911A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- novel anti
- fragments
- human
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005911A true MX2019005911A (es) | 2019-07-08 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005911A MX2019005911A (es) | 2016-11-21 | 2017-11-21 | Anticuerpos anti_cd137 novedosos y usos de estos. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11535678B2 (enExample) |
| EP (1) | EP3541844A2 (enExample) |
| JP (1) | JP7068303B2 (enExample) |
| KR (1) | KR102679632B1 (enExample) |
| CN (1) | CN109963873B (enExample) |
| AU (1) | AU2017360094B2 (enExample) |
| BR (1) | BR112019010265A2 (enExample) |
| CA (1) | CA3044339A1 (enExample) |
| GB (1) | GB201619648D0 (enExample) |
| IL (1) | IL266738B2 (enExample) |
| MX (1) | MX2019005911A (enExample) |
| NZ (1) | NZ754051A (enExample) |
| RU (1) | RU2019116624A (enExample) |
| WO (1) | WO2018091740A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201831513A (zh) | 2016-06-20 | 2018-09-01 | Ｆ星貝塔有限公司 | 結合物件(一) |
| WO2018127787A1 (en) * | 2017-01-06 | 2018-07-12 | Eutilex Co., Ltd. | Anti-human 4-1 bb antibodies and use thereof |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| PE20200839A1 (es) | 2017-08-01 | 2020-08-13 | Lilly Co Eli | Anticuerpos anti-cd137 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| CN112020517B (zh) | 2018-03-23 | 2024-10-29 | 伊莱利利公司 | 用于与抗pd-l1抗体组合的抗cd137抗体 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| KR102697702B1 (ko) | 2018-08-10 | 2024-08-22 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| JP7387743B2 (ja) * | 2018-09-12 | 2023-11-28 | ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド | 抗ｔｎｆｒｓｆ９抗体及びその使用 |
| CN120098128A (zh) * | 2019-01-02 | 2025-06-06 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| SG11202110287QA (en) | 2019-04-24 | 2021-10-28 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CN118791614A (zh) | 2019-06-26 | 2024-10-18 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| JP7432716B2 (ja) * | 2019-11-13 | 2024-02-16 | 合肥瀚科邁博生物技術有限公司 | ヒト４－１ｂｂに結合可能な分子及びその応用 |
| US11396647B2 (en) | 2020-01-07 | 2022-07-26 | Board Of Regents, The University Of Texas System | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| EP4096789A4 (en) | 2020-01-29 | 2023-10-11 | Board of Regents, The University of Texas System | USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS |
| CN115362270A (zh) | 2020-01-29 | 2022-11-18 | 得克萨斯州大学系统董事会 | Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途 |
| BR112022016491A2 (pt) * | 2020-02-28 | 2022-10-11 | Shanghai Henlius Biotech Inc | Construto anti-cd137 e usos do mesmo |
| EP4153316A1 (en) | 2020-05-19 | 2023-03-29 | Boehringer Ingelheim International GmbH | Binding molecules for the treatment of cancer |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| JP2023531042A (ja) * | 2020-06-30 | 2023-07-20 | 諾納生物（蘇州）有限公司 | ４－１ｂｂ結合タンパク質及びその用途 |
| JP7744991B2 (ja) * | 2021-01-08 | 2025-09-26 | 北京韓美薬品有限公司 | ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント |
| US20240287199A1 (en) | 2021-06-18 | 2024-08-29 | Alligator Bioscience Ab | Novel combination therapies and uses thereof |
| WO2023056361A1 (en) | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
| GB2629959A (en) * | 2021-12-29 | 2024-11-13 | Curateq Biologics Private Ltd | C1Q binding assay |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025531938A (ja) * | 2022-09-22 | 2025-09-25 | アブリンク バイオテック カンパニー リミテッド | 抗４－１ｂｂナノボディ、その製造及び使用 |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| TWI423814B (zh) | 2006-09-01 | 2014-01-21 | Genticel | 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子 |
| US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| US11008396B2 (en) | 2015-05-21 | 2021-05-18 | Alligator Bioscience Ab | Polypeptides |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 BR BR112019010265-5A patent/BR112019010265A2/pt active Search and Examination
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
-
2022
- 2022-11-10 US US18/054,373 patent/US12509526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3541844A2 (en) | 2019-09-25 |
| IL266738A (en) | 2019-07-31 |
| BR112019010265A2 (pt) | 2019-09-17 |
| US12509526B2 (en) | 2025-12-30 |
| AU2017360094B2 (en) | 2024-12-12 |
| US10689454B2 (en) | 2020-06-23 |
| IL266738B1 (en) | 2024-02-01 |
| RU2019116624A (ru) | 2020-12-21 |
| GB201619648D0 (en) | 2017-01-04 |
| AU2017360094A1 (en) | 2019-06-20 |
| CN109963873A (zh) | 2019-07-02 |
| NZ754051A (en) | 2023-05-26 |
| KR102679632B1 (ko) | 2024-06-28 |
| IL266738B2 (en) | 2024-06-01 |
| RU2019116624A3 (enExample) | 2021-01-29 |
| US20190352411A1 (en) | 2019-11-21 |
| KR20190086691A (ko) | 2019-07-23 |
| JP2020501531A (ja) | 2020-01-23 |
| CA3044339A1 (en) | 2018-05-24 |
| WO2018091740A3 (en) | 2018-06-28 |
| US20190352414A1 (en) | 2019-11-21 |
| US20230295325A1 (en) | 2023-09-21 |
| JP7068303B2 (ja) | 2022-05-16 |
| WO2018091740A2 (en) | 2018-05-24 |
| CN109963873B (zh) | 2023-12-26 |
| US11535678B2 (en) | 2022-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005911A (es) | Anticuerpos anti_cd137 novedosos y usos de estos. | |
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| EP4566621A3 (en) | Dll3/cd3 binding proteins for the treatment of cancer | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| MX393609B (es) | Anticuerpos anti pd-1 y anti-lag3 para el tratamiento de cancer | |
| MX2018000470A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22). | |
| MX2022008523A (es) | Compuestos que interactuan con glicanos y metodos de uso. | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| MA40074A (fr) | Composés liant ras multivalents | |
| MX2016012830A (es) | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. | |
| AU2015347015A8 (en) | Antibody drug conjugates | |
| MX2018000590A (es) | Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79). | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| SG10201806454RA (en) | Anti-tenascin c antibodies and uses thereof | |
| WO2018071822A8 (en) | ANTIBODIES BINDING TO THE ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF | |
| MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2024002182A (es) | Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii). |